EFFECT OF ULINASTATIN COMBINED WITH HAEMODIALYSIS ON
SEVERE ACUTE PANCREATITIS
HANFEI XING1, HUI WEN2*, DUJIE WANG1, HONGHUI WANG1, MENG ZHAO2
1Department of Thyroid Breast Surgery, Central Hospital of Binzhou City, Binzhou, Shandong, 251700, China
2Intensive Care Unit, Central Hospital of Binzhou City, Binzhou, Shandong, 251700, China
*corresponding author: huiwen@yahoo.com
Download Full Article

Abstract:
This study aimed to explore the clinical efficacy of ulinastatin and haemodialysis in the treatment of severe acute pancreatitis
(SAP). 60 SAP patients treated in the Binzhou Central Hospital in Shandong Province, China, during June 2015 and
December 2016 were randomly selected as the research subjects in this study and divided into a conventional treatment group
A and an ulinastatin combined with haemodialysis treatment group B. The clinical data of the patients were compared and the
blood amylase, urine amylase, serum urea nitrogen, serum lactose, serum creatinine levels, CD4+, CD8+, interleukin-1 (IL-1)
and tumour necrosis factor-alpha (TNF-α) ratio were compared after treatment. The levels of serum amylase, urinary
amylase, serum creatinine, serum urea nitrogen and serum lactose of group B decreased with the increase of treatment time
and showed a significant difference when compared with the conventional treatment group (p < 0.05); IL-1 and TNF-α levels
decreased, CD4+, CD8+ and the ratio of both increased gradually. The improvement of the clinical symptoms such as fever,
abdominal pain and swelling in group B was shorter than in group A (p < 0.05). The cure rate of group B was about 50% and
its total effective rate was about 93.3% while those of group A was about 26.7% and 53.3% (p < 0.05). Ulinastatin combined
with haemodialysis has a good clinical effect on severe acute pancreatitis.

Top